Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 9019 results

  1. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [GID-TA11987]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [GID-TA11976]

    Awaiting development Reference number: GID-TA11976 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  5. NICE Funding Variation Request Consultation: methods / process manual consultation

    We are listening to your views on this NICE process and methods. Comments close 19 June 2026.

    In consultation

  6. Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  14 July 2026

    Technology appraisal guidance
    Awaiting development

  9. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development

  11. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]

    Awaiting development Reference number: GID-TA11194 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

    Quality standard
    Awaiting development